28 results
6-K
EX-99.2
IFRX
InflaRx N.V.
5 Jun 24
InflaRx Hosts R&D Event Highlighting the Promise of INF904
5:07pm
community activating complement and PRRs* to induce inflammatory cytokines (IL-6, IL-23) promoting Th17 cell expansion and neutrophil recruitment … – Current understanding of the C5a/C5aR1 biology Page 31
C5aR1 drives disease development in experimental EBA at several levels The recruitment
6-K
EX-99.1
IFRX
InflaRx N.V.
5 Aug 22
Current report (foreign)
6:07am
at regular operational levels, and the recruitment of patients and new clinical trial sites also continued in the first six months of 2022 through the date
6-K
EX-99.1
IFRX
InflaRx N.V.
12 May 22
Current report (foreign)
8:30am
levels, and the recruitment of patients and new clinical trial sites also continued in the first quarter of 2022 through the date of issuance
6-K
EX-99.1
af22n0cdwly
5 Jan 22
Current report (foreign)
7:30am
6-K
EX-99.1
htt9rg d55
5 Nov 21
Current report (foreign)
7:30am
6-K
EX-99.2
w3ixr9l
5 Nov 21
Current report (foreign)
7:30am
6-K
EX-99.1
8g9bov2
5 Aug 21
Current report (foreign)
8:23am
6-K
EX-99.3
yy2v7th
5 Aug 21
Current report (foreign)
8:23am
6-K
EX-99.1
tafjvn4czaff
12 May 21
Current report (foreign)
4:30pm
6-K
EX-99.3
heei1
12 May 21
Current report (foreign)
4:30pm
6-K
EX-99.1
6kh9k0a70an
25 Mar 21
InflaRx Reports Full Year 2020 Financial & Operating Results
7:28am
424B5
3gcf6yw48g1iweya9e
26 Feb 21
Prospectus supplement for primary offering
5:10pm
424B5
k11rvgpx5hec
24 Feb 21
Prospectus supplement for primary offering
5:16pm
6-K
xxba2vto9u4ss2y
24 Feb 21
Current report (foreign)
4:16pm
6-K
EX-99.1
4y4uqout3
11 Jan 21
InflaRx Provides Update on Vilobelimab (IFX-1) Development
7:30am
6-K
EX-99.1
6vdpokzt 92uy8
29 Oct 20
Current report (foreign)
7:05am
6-K
EX-99.1
cx127i0n45xyrui2x3o
30 Jul 20
Current report (foreign)
7:36am